{         "clinical_results": {             "participant_flow": {                 "recruitment_details":"",                 "pre_assignment_details":"",                 "group_list": {                     "group": [                                              ]                 },                 "period_list":{                     "period": [                                              ]                 }             },             "baseline" : {                 "population":"",                 "group_list": {                     "group": [                                              ]                 },                 "analyzed_list": {                     "analyzed": [                                              ]                 },                 "measure_list": {                     "measure": [                                          ]                 }             },             "outcome_list": {                 "outcome": [                                      ]             },             "reported_events":{                 "time_frame":"",                 "desc":"",                 "group_list": {                     "group": [                                          ]                 },                 "serious_events":{                     "frequency_threshold":"",                     "default_vocab":"",                     "default_assessment":"",                     "category_list": {                         "category": [                                                  ]                     }                 },                 "other_events":{                     "frequency_threshold":"",                     "default_vocab":"",                     "default_assessment":"",                     "category_list": {                         "category": [                                                  ]                     }                 }             },             "certain_agreements":{                 "pi_employee":"",                 "restrictive_agreement":""             },             "limitations_and_caveats":"",             "point_of_contact":{                 "name_or_title":"",                 "organization":"",                 "phone":"",                 "email":""             }         },         "patient_data": {             "sharing_ipd":"",             "ipd_description":""         },         "study_docs": {             "study_doc": [                              ]         },         "responsible_party": {             "responsible_party_type":"Principal Investigator",             "investigator_affiliation":"Cairo University",             "investigator_full_name":"Aya Mohammed Abdel Magid Abdel Hamid",             "invewastigator_title":"Teaching Assistant"         },         "intervention": [         {             "intervention_type":"Drug",             "intervention_name":"Fenofibrate",             "description":"",             "arm_group_label": [                                      "Fenofibrate group"             ],             "other_name": [                          ]             },{             "intervention_type":"Drug",             "intervention_name":"Simvastatin",             "description":"",             "arm_group_label": [                                      "Simvastatin group"             ],             "other_name": [                          ]             }         ],         "eligibility": {             "study_pop": {                 "textblock":""             },             "sampling_method":"",             "criteria":{                 "textblock":""             },             "gender":"All",             "gender_based":"",             "minimum_age":"18 Years",             "maximum_age":"65 Years",             "healthy_volunteers":"No"         },         "overall_official": [                      ],         "overall_contact": {             "first_name":"",             "middle_name":"",             "last_name":"",             "degrees":"",             "phone":"",             "phone_ext":"",             "email":""         },         "overall_contact_backup": {             "first_name":"",             "middle_name":"",             "last_name":"",             "degrees":"",             "phone":"",             "phone_ext":"",             "email":""         },         "oversight_info":{             "has_dmc":"",             "is_fda_regulated_drug":"",             "is_fda_regulated_device":"",             "is_unapproved_device":"",             "is_ppsd":"",             "is_us_export":""         },         "arm_group":{             "arm_group_label":"Fenofibrate group",             "arm_group_type":"Active Comparator",             "description":"Group I (30 patients): Patients receiving fenofibrate (100 mg) taken on dialysis days after the dialysis session (three times per week)."         },         "expanded_access_info":{             "expanded_access_type_individual":"",             "expanded_access_type_intermediate":"",             "expanded_access_type_treatment":""         },         "study_design_info":{             "allocation":"Randomized",             "intervention_model":"Parallel Assignment",             "intervention_model_description":"",             "primary_purpose":"Treatment",             "observational_model":"",             "time_perspective":"",             "masking":"None (Open Label)",             "masking_description":""         },         "required_header":{             "download_date":"ClinicalTrials.gov processed this data on May 09, 2018",             "link_text":"Link to the current ClinicalTrials.gov record.",             "url":"https://clinicaltrials.gov/show/NCT02886299"         },         "id_info":{             "org_study_id":"CL (746)",             "secondary_id":[                              ],             "nct_id":"NCT02886299",             "nct_alias":[                              ]         },         "brief_title":"Randomized Comparative Efficacy and Safety Study of Intermittent Simvastatin and Fenofibrate in Hemodialysis",         "acronym":"",         "official_title":"Comparative Study of Effects and Safety of Intermittent Low Dose Therapy of Fenofibrate and Simvastatin on Chronic Hemodialysis Patients",         "sponsors":{             "lead_sponsor":{                 "agency":"Cairo University",                 "agency_class":"Other"             },             "collaborator":[                              ]         },         "source":"Cairo University",         "why_stopped":"",         "target_duration":"",         "overall_status":"Completed",         "last_known_status":"",         "phase":"Phase 4",         "study_type":"Interventional",         "has_expanded_access":"No",         "biospec_retention":"",         "number_of_arms":"2",         "number_of_groups":"",         "verification_date":"September 2016",         "study_first_submitted":"August 29, 2016",         "study_first_submitted_qc":"August 31, 2016",         "results_first_submitted":"",         "results_first_submitted_qc":"",         "disposition_first_submitted":"",         "disposition_first_submitted_qc":"",         "last_update_submitted":"September 1, 2016",         "last_update_submitted_qc":"September 1, 2016",         "enrollment":{             "type":"Actual",             "text_node_value":"60"         },         "study_first_posted":{             "type":"Estimate",             "text_node_value":"September 1, 2016"         },         "results_first_posted":{             "type":"",             "text_node_value":""         },         "disposition_first_posted":{             "type":"",             "text_node_value":""         },         "last_update_posted":{             "type":"Estimate",             "text_node_value":"September 5, 2016"         },         "completion_date":{             "type":"Actual",             "text_node_value":"January 2016"         },         "start_date":{             "type":"",             "text_node_value":"October 2013"         },         "primary_completion_date":{             "type":"Actual",             "text_node_value":"January 2016"         },         "brief_summary":{             "textblock":"       Sixty chronic hemodialysis patients were randomly assigned to receive fenofibrate 100 mg       (group 1, n = 30) or simvastatin 20 mg (group 2, n = 30) three times/week after their       dialysis session. The safety and efficacy of drugs on lipid profile, oxidized low density       lipoproteins (ox-LDL), glutathione peroxidase (GSH-Px) and C-reactive protein (CRP) were       compared before and after 16-week treatment.     "         },         "detailed_description":{             "textblock":"       This is a prospective randomized open label parallel study.        The selected patients will be randomly allocated to one of two groups          -  Group I (30 patients): Patients receiving fenofibrate (100 mg) taken on dialysis days            after the dialysis session (three times per week).          -  Group II (30 patients): Patients receiving simvastatin (20 mg) taken on dialysis days            after the dialysis session (3 times per week).        A careful history of all patients including demographic characteristics, physical       examination, chief complaint, past medical history, drug history, familial history, social       history, disease(s).        Monitoring Parameters:        For efficacy, the following parameters are measured:          1. Lipid profile (total cholesterol, HDL, TG and LDL from Friedwald formula [10] {LDL-C=            TC-[HDL + TG\5]). (measured at baseline and every month for 4 months)          2. C-reactive protein (CRP). (measured at baseline and after 4 months)          3. Oxidative stress markers: oxidized LDL and human glutathione peroxidase (measured at            baseline and after 4 months).        For safety: (measured at baseline and every month for 4 months)          1. Observe for signs & symptoms of muscle toxicity and measure phosphocreatine kinase            (CPK).          2. Liver function tests: ALT, AST, ALP & albumin.          3. Urea & serum creatinine. (to monitor renal function)          4. Hemoglobin          5. Other measurements: Body mass index (BMI), Blood Pressure, electrolytes            (Sodium,potassium, calcium, phosphorous) and assess patient compliance by tablet            counting.        Statistical analysis will be used to compare the effects of simvastatin and fenofibrate on       lipid profile, inflammatory marker (CRP) and oxidative stress markers (oxidized LDL and       glutathione peroxidase). In addition, comparing their safety on renal and hepatic functions,       phosphocreatine kinase, blood pressure and blood glucose level.     "         },         "biospec_descr":{             "textblock":""         },         "keyword": [                      "Fibrates",             "Statins",             "Hemodialysis",             "Dyslipidemia",             "Improved Oxidative Stress",             "Egypt"         ],         "condition": [                      "Fenofibrate/Simvastatin Comparison"         ],         "primary_outcome": [                      {             "measure":"oxidative stress markers (serum ox-LDL and GSH-Px)",             "time_frame":"16 weeks",             "description":""             },             {             "measure":"C-reactive protein",             "time_frame":"16 weeks",             "description":""             }         ],         "secondary_outcome": [                  ],         "other_outcome": [                  ],         "reference": [                  ],         "results_reference": [                  ],         "link": [                  ],         "location": [                  ],          "location_countries": [                  ],         "removed_countries": [                  ],         "condition_browse": [                  ],         "intervention_browse": [                      "Simvastatin",             "Fenofibrate"         ]         }     